IF 3.2 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS ESC Heart Failure Pub Date : 2025-03-01 DOI:10.1002/ehf2.15247
Yi-Peng Gao, Hong-Yun Liu, Xiao-Jun Bi, Jie Sun, Ying Zhu, Wei Zhou, Ya-Ting Fan, Xue-Qing Cheng, Pei-Na Huang, Ya-Ni Liu, You-Bin Deng
{"title":"H<sub>2</sub>FPEF and HFA-PEFF scores for heart failure risk stratification in hypertrophic cardiomyopathy patients.","authors":"Yi-Peng Gao, Hong-Yun Liu, Xiao-Jun Bi, Jie Sun, Ying Zhu, Wei Zhou, Ya-Ting Fan, Xue-Qing Cheng, Pei-Na Huang, Ya-Ni Liu, You-Bin Deng","doi":"10.1002/ehf2.15247","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>H<sub>2</sub>FPEF and HFA-PEFF scores have demonstrated prognostic value in heart failure (HF) with preserved ejection fraction. This study aimed to explore the value of the H<sub>2</sub>FPEF and HFA-PEFF scores for HF risk stratification in patients with hypertrophic cardiomyopathy (HCM).</p><p><strong>Methods and results: </strong>In this cohort study, 1068 HCM patients were included. Then the H<sub>2</sub>FPEF and HFA-PEFF scores were calculated to categorize patients into low, intermediate, and high score groups. The primary endpoint was a composite of the first HF hospitalization and all-cause death. 594 (55.6%) patients were classified discordantly. After a follow-up period of 3.1 ± 2.1 years, 85 (8.0%) patients were admitted for HF for the first time, and 62 (5.8%) patients died. Rates of first HF hospitalization and all-cause death per 1000 person-years for the low, intermediate, and high H<sub>2</sub>FPEF score groups were 25.0 (95% confidence interval [CI]: 14.5-35.4), 52.0 (95% CI: 41.6-62.3), and 148.1 (95% CI: 77.7-218.5), respectively. For the low-intermediate and high HFA-PEFF score groups, rates were 19.3 (95% CI: 11.6-27.0) and 69.3 (95% CI: 56.4-82.1), respectively. Intermediate H<sub>2</sub>FPEF score (hazard ratio [HR]: 1.820, 95% CI: 1.135-2.919; P = 0.013), high H<sub>2</sub>FPEF score (HR: 3.464, 95% CI: 1.774-6.765; P < 0.001), and high HFA-PEFF score (HR: 2.414, 95% CI: 1.501-3.882; P < 0.001) were each independently associated with an increased risk of the primary endpoint. Intermediate-high H<sub>2</sub>FPEF score demonstrated an equal risk for the primary endpoint compared to the high HFA-PEFF score (HR: 0.826, 95% CI: 0.636-1.072; P > 0.05). Obesity (HR: 1.958, 95% CI: 1.140-3.363; P = 0.015), atrial fibrillation (HR: 1.686, 95% CI: 1.071-2.654; P = 0.024), pulmonary hypertension (HR: 1.613, 95% CI: 1.032-2.521; P = 0.036) of the H<sub>2</sub>FPEF score, and the morphological major criterion (HR: 1.601, 95% CI: 1.084-2.364; P = 0.018) and functional major criterion (HR: 2.340, 95% CI: 1.442-3.797; P < 0.001) of the HFA-PEFF score were independent predictors of the primary endpoint. A new algorithm was constructed using the independent predictors from both scores, with the functional major criterion weighted as 2 points and the others as 1 point. The H<sub>2</sub>FPEF score, HFA-PEFF score, and the new algorithm demonstrated C-indices of 0.594, 0.651, and 0.681, respectively.</p><p><strong>Conclusions: </strong>There is discordance in the classification of patients with HCM using the H<sub>2</sub>FPEF and HFA-PEFF scores. Both scores demonstrated prognostic value in risk stratification for HF hospitalization and all-cause death in HCM patients. Future studies should develop and validate a new algorithm integrating both scores.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ehf2.15247","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:H2FPEF和HFA-PEFF评分对射血分数保留型心力衰竭(HF)具有预后价值。本研究旨在探讨 H2FPEF 和 HFA-PEFF 评分对肥厚型心肌病(HCM)患者进行 HF 风险分层的价值:在这项队列研究中,共纳入了 1068 名 HCM 患者。然后计算 H2FPEF 和 HFA-PEFF 评分,将患者分为低分、中分和高分组。主要终点是首次心房颤动住院和全因死亡的综合评分。594名(55.6%)患者的分类不一致。随访 3.1 ± 2.1 年后,85 例(8.0%)患者首次因心房颤动住院,62 例(5.8%)患者死亡。H2FPEF评分低、中、高组的首次心房颤动住院率和每千人年全因死亡率分别为25.0(95% 置信区间[CI]:14.5-35.4)、52.0(95% CI:41.6-62.3)和148.1(95% CI:77.7-218.5)。中低和高 HFA-PEFF 评分组的发病率分别为 19.3(95% CI:11.6-27.0)和 69.3(95% CI:56.4-82.1)。中度 H2FPEF 评分(危险比 [HR]:1.820,95% CI:1.135-2.919;P = 0.013)、高度 H2FPEF 评分(HR:3.464,95% CI:1.774-6.765;P 2FPEF 评分与高度 HFA-PEFF 评分相比,主要终点风险相同(HR:0.826,95% CI:0.636-1.072;P > 0.05)。肥胖(HR:1.958,95% CI:1.140-3.363;P = 0.015)、心房颤动(HR:1.686,95% CI:1.071-2.654;P = 0.024)、肺动脉高压(HR:1.613,95% CI:1.032-2.521;P = 0.036)的 H2FPEF 评分和形态学主要标准(HR:1.601,95% CI:1.084-2.364;P = 0.018)和功能性主要标准(HR:2.340,95% CI:1.442-3.797;P 2FPEF评分、HFA-PEFF评分和新算法的C指数分别为0.594、0.651和0.681):结论:使用 H2FPEF 和 HFA-PEFF 评分对 HCM 患者进行分类存在不一致。这两个评分在对 HF 住院和 HCM 患者全因死亡进行风险分层时均具有预后价值。未来的研究应开发并验证一种整合两种评分的新算法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
H2FPEF and HFA-PEFF scores for heart failure risk stratification in hypertrophic cardiomyopathy patients.

Aims: H2FPEF and HFA-PEFF scores have demonstrated prognostic value in heart failure (HF) with preserved ejection fraction. This study aimed to explore the value of the H2FPEF and HFA-PEFF scores for HF risk stratification in patients with hypertrophic cardiomyopathy (HCM).

Methods and results: In this cohort study, 1068 HCM patients were included. Then the H2FPEF and HFA-PEFF scores were calculated to categorize patients into low, intermediate, and high score groups. The primary endpoint was a composite of the first HF hospitalization and all-cause death. 594 (55.6%) patients were classified discordantly. After a follow-up period of 3.1 ± 2.1 years, 85 (8.0%) patients were admitted for HF for the first time, and 62 (5.8%) patients died. Rates of first HF hospitalization and all-cause death per 1000 person-years for the low, intermediate, and high H2FPEF score groups were 25.0 (95% confidence interval [CI]: 14.5-35.4), 52.0 (95% CI: 41.6-62.3), and 148.1 (95% CI: 77.7-218.5), respectively. For the low-intermediate and high HFA-PEFF score groups, rates were 19.3 (95% CI: 11.6-27.0) and 69.3 (95% CI: 56.4-82.1), respectively. Intermediate H2FPEF score (hazard ratio [HR]: 1.820, 95% CI: 1.135-2.919; P = 0.013), high H2FPEF score (HR: 3.464, 95% CI: 1.774-6.765; P < 0.001), and high HFA-PEFF score (HR: 2.414, 95% CI: 1.501-3.882; P < 0.001) were each independently associated with an increased risk of the primary endpoint. Intermediate-high H2FPEF score demonstrated an equal risk for the primary endpoint compared to the high HFA-PEFF score (HR: 0.826, 95% CI: 0.636-1.072; P > 0.05). Obesity (HR: 1.958, 95% CI: 1.140-3.363; P = 0.015), atrial fibrillation (HR: 1.686, 95% CI: 1.071-2.654; P = 0.024), pulmonary hypertension (HR: 1.613, 95% CI: 1.032-2.521; P = 0.036) of the H2FPEF score, and the morphological major criterion (HR: 1.601, 95% CI: 1.084-2.364; P = 0.018) and functional major criterion (HR: 2.340, 95% CI: 1.442-3.797; P < 0.001) of the HFA-PEFF score were independent predictors of the primary endpoint. A new algorithm was constructed using the independent predictors from both scores, with the functional major criterion weighted as 2 points and the others as 1 point. The H2FPEF score, HFA-PEFF score, and the new algorithm demonstrated C-indices of 0.594, 0.651, and 0.681, respectively.

Conclusions: There is discordance in the classification of patients with HCM using the H2FPEF and HFA-PEFF scores. Both scores demonstrated prognostic value in risk stratification for HF hospitalization and all-cause death in HCM patients. Future studies should develop and validate a new algorithm integrating both scores.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ESC Heart Failure
ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine
CiteScore
7.00
自引率
7.90%
发文量
461
审稿时长
12 weeks
期刊介绍: ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
期刊最新文献
Refractory heart failure due to acquired aortic coarctation after total arch replacement: find the right antidote! Delayed cardiac consequences unveiled by magnetic resonance imaging in a high-voltage electric shock survivor. Impact of immigration on outcomes following acute decompensated heart failure: A retrospective cohort study. Mono and combination therapies in pulmonary arterial hypertension patients with comorbidities: A COMPERA analysis. Electron microscopic findings predict clinical outcomes in patients with non-ischaemic cardiomyopathy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1